Showing 9291-9300 of 21415 results for "".
Evaluating a Lower-Intensity Treatment Regimen in AML: Phase 2 Results from PARADIGM
https://reachmd.com/programs/project-oncology/azacitidine-venetoclax-aml-phase-2-paradigm-trial/39973/At the 2025 American Society of Hematology Annual Meeting, researchers presented pivotal findings from the phase 2 PARADIGM trial on azacitidine and venetoclax in patients with acute myeloid leukemia (AML). In this AudioAbstract, Ryan Quigley shares key findings on how this lower-intensity regimen cDiscussing the Complications of IBS Mimickers
https://reachmd.com/programs/gi-insights/discussing-the-complications-of-ibs-mimickers/24057/What are IBS mimickers? Tune in.IBD and Pregnancy: Key Considerations for Patient Management
https://reachmd.com/programs/gi-insights/ibd-and-pregnancy-key-considerations-for-patient-management/32324/Learn about inflammatory bowel disease, its impact on pregnancy, and best practices for monitoring and treating pregnant patients.The Hidden Costs of IV-Push Controlled Substance Waste in Hospitals
https://reachmd.com/programs/clinicians-roundtable/iv-push-controlled-substance-waste-costs/60597/IV-push controlled substance waste creates far-reaching challenges that extend well beyond medication disposal. In fact, a recent multicenter study evaluated more than 4,400 controlled substance transactions across 16 hospitals and found significant documentation variability, frequent partial-dose wBreakthrough Technology Improves Concussion Assessment and Player Safety
https://reachmd.com/programs/medical-industry-feature/breakthrough-technology-improves-concussion-assessment-and-player-safety/29926/Learn about a new eye-tracking tool that can detect a biomarker indicative of concussion, bringing clinicians closer to objective diagnosis and more informed decision-making.The Rationale for Complement Inhibition in the Management of IgA Nephropathy
https://reachmd.com/programs/kdigo-conversations-nephrology/the-rationale-for-complement-inhibition-in-the-management-of-iga-nephropathy/70149/In this episode of KDIGO Conversations in Nephrology, host Dr. Brad Rovin (The Ohio State University Wexner Medical Center, US) welcomes Dr. Dana Rizk (University of Alabama at Birmingham, US) to discuss the rationale for using complement inhibition in the management of IgA nephropathy. Dr. Rizk expAdvancing Precision Medicine in Fibrotic Interstitial Lung Disease
https://reachmd.com/programs/clinicians-roundtable/precision-medicine-fibrotic-interstitial-lung-disease/67686/Advances in biomarkers and precision medicine are creating new opportunities in fibrotic interstitial lung disease, but translating these insights into clinical practice remains a challenge. So what will it take to integrate available data into care in a way that’s sustainable, feasible, and adaptabPediatric Influenza: Risks, Realities, and Prevention
https://reachmd.com/programs/vaccination/pediatric-influenza-risks-realities-prevention/36271/Pediatric influenza carries a significant clinical burden, with children under four experiencing one of the highest rates of influenza-related illness, healthcare visits, and hospitalization.1,2 Seasonal influenza vaccination remains an evidence-based strategy to reduce illness and severe outcomes,Implementing Lifestyle Medicine in Breast Cancer Survivorship Care
https://reachmd.com/programs/project-oncology/lifestyle-medicine-breast-cancer-survivorship-care/50994/With growing evidence supporting lifestyle medicine in breast cancer outcomes, integrating these strategies into survivorship care is increasingly important. That’s why Dr. Amy Comander joins us to highlight common barriers faced by both clinicians and patients, recent data showing the impact of cliWhen to Adjust Treatment in Irritable Bowel Syndrome with Constipation
https://reachmd.com/programs/clinicians-roundtable/adjust-treatment-irritable-bowel-syndrome-constipation/51045/Knowing when to adjust treatment in patients with irritable bowel syndrome with constipation (IBS-C) can make a meaningful difference in outcomes. However, various challenges can make it difficult to find the right moment to reassess and pivot therapy. To make the process a little simpler, Dr. Brian